Metabolic marker composition for predicting neoadjuvant chemoradiotherapy efficacy of rectal cancer and application thereof
By combining metabolic biomarkers and metabolomics technology, the efficacy of neoadjuvant chemoradiotherapy for rectal cancer can be predicted at an early stage, solving the problem of time-consuming and costly efficacy assessment in existing technologies, and improving the accuracy of efficacy prediction and patient survival rate.
Patent Information
- Application Number
- CN202510638229.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-19
- Publication Date
- 2026-07-17
AI Technical Summary
Current technology makes it difficult to accurately determine the efficacy of neoadjuvant chemoradiotherapy for rectal cancer before treatment, resulting in some patients incurring unnecessary treatment costs and adverse reactions. Furthermore, imaging examinations are costly and time-consuming, causing patients to miss other treatment opportunities.
The study utilizes a combination of metabolic biomarkers, including 2,3-dihydroxybutyric acid, alanine, choline, creatine, ceramide d42:1, glutamine, hippuric acid, myristic acid, sphingomyelin d32:1, and triglycerides 60:6, to analyze blood samples using metabolomics technology. This allows for the construction of a predictive model and enables early prediction of the efficacy of neoadjuvant chemoradiotherapy.
It improves the sensitivity and specificity of predicting the efficacy of neoadjuvant chemoradiotherapy, saves treatment time and costs, improves patient survival rates, simplifies the testing process, and reduces technical costs.
Smart Images
Figure CN122410035A_ABST